CStone Pharmaceuticals
CSPHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2 | $3 | $5 | $9 |
| - Cash | $0 | $1 | $1 | $1 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $2 | $5 | $9 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -12.2% | -3.6% | 97.5% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 59% | 65.6% | 57.8% | 56.2% |
| EBITDA | -$0 | -$0 | -$1 | -$2 |
| % Margin | -6.4% | -64.1% | -176.5% | -777.6% |
| Net Income | -$0 | -$0 | -$1 | -$2 |
| % Margin | -22.4% | -79.2% | -187.5% | -787.8% |
| EPS Diluted | -0.072 | -0.29 | -0.77 | -1.65 |
| % Growth | 75.3% | 62.3% | 53.3% | – |
| Operating Cash Flow | -$0 | -$1 | -$1 | -$1 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$1 | -$1 | -$2 |